首頁 > 市場調查報告書 > 製藥

基因治療學和RNAi 再生醫學細胞療法基因療法

市場調查報告書

商品編碼

2058198

腫瘤細胞和基因治療市場：按治療類型、技術、適應症、最終用戶和地區分類。

Cell and Gene Therapy for Oncology Market, By Therapy Type, By Technology, By Indication, By End User, By Geography

出版日期: 2026年05月08日 | 出版商:

Coherent Market Insights | 英文 156 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

預計到 2026 年，腫瘤細胞和基因治療市場規模將達到 86.419 億美元，到 2033 年將達到 1,384.25 億美元。預計從 2026 年到 2033 年，該市場將以 44.7% 的複合年成長率成長。

報告範圍		報告詳情
基準年：	2025	2026年市場規模：	86.419億美元
歷史數據時期：	2020年至2024年	預測期：	2026年至2033年
2026年至2033年預測期間的複合年成長率：	44.70%	2033年市場規模預測：	1384.25億美元

全球腫瘤細胞和基因治療市場是癌症治療領域中成長最快的市場之一，其成長主要受癌症患者數量不斷增加以及對個人化和標靶治療方案需求日益成長的推動。該領域的領導者正致力於開發最先進治療，例如 CAR-T 療法、TCR 療法和基因修飾免疫療法，這些療法與現有治療方法相比，能夠提供更優的療效。

基因編輯、病毒載體開發和細胞工程等領域的技術進步正在革新癌症治療流程。此外，臨床試驗參與度的提高、核准的批准以及生物製藥公司的投資等許多因素也在推動市場成長。精準醫療的日益普及、生產技術的改進以及策略聯盟的建立，也正在推動細胞和基因癌症治療市場的創新。

市場動態

全球腫瘤細胞和基因治療市場正受到日益嚴重的全球癌症負擔以及對更精準腫瘤治療需求不斷成長的推動。除了大眾對新型癌症治療方法的認知度不斷提高外，CAR-T細胞療法、基因編輯和病毒載體等技術的進步也進一步促進了市場成長。此外，生物製藥產業的領導者也正在增加臨床試驗，並增加對創新癌症療法的投資。

限制市場成長的因素包括癌症細胞和基因療法的高昂成本、高昂的生產成本以及圍繞這些療法的嚴格法規結構。此外，人們也開始關注這些治療方法相關的不良副作用，例如細胞激素釋放症候群，並對其安全性表示擔憂。儘管如此，異體移植和預構建療法的興起、其在固體癌治療中的應用範圍擴大以及對生產設施投資的增加，都為市場帶來了巨大的成長機會。

本次調查的主要特點

本研究確定了各個細分市場的潛在商機，並說明了該市場具有吸引力的投資提案矩陣。
此外，本研究還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域展望以及主要參與者採取的競爭策略的重要見解。
本研究根據以下參數分析了全球腫瘤細胞和基因治療市場主要公司的概況：公司亮點、產品系列、關鍵亮點、財務表現和策略。
透過利用本報告中的見解，企業行銷負責人和經營團隊將能夠就未來的產品發布、產品升級、市場擴張和行銷策略做出明智的決策。
本報告面向該產業的各類相關人員，包括投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。
相關人員可以利用各種策略矩陣來分析全球腫瘤細胞和基因治療市場，從而更輕鬆地做出決策。

北美洲
- 美國
- 加拿大
拉丁美洲
- 巴西
- 阿根廷
- 墨西哥
- 其他拉丁美洲國家
歐洲
- 德國
- 英國
- 西班牙
- 法國
- 義大利
- 俄羅斯
- 其他歐洲國家
亞太地區
- 中國
- 印度
- 日本
- 澳洲
- 韓國
- ASEAN
- 其他亞太國家
中東
- 海灣合作理事會國家
- 以色列
- 其他中東國家
非洲
- 南非
- 北非
- 中非

第9章競爭情勢

Gilead Sciences
Novartis AG
Bristol Myers Squibb
Johnson & Johnson
Legend Biotech
bluebird bio
CRISPR Therapeutics
Allogene Therapeutics
Iovance Biotherapeutics
Adaptimmune Therapeutics

第10章分析師建議

機會分析
分析師意見
Coherent Opportunity Map

第11章參考文獻與調查方法

參考
調查方法
關於本公司

簡介目錄

Product Code: CMI9477

Cell and Gene Therapy for Oncology Market is estimated to be valued at USD 8,641.9 Mn in 2026 and is expected to reach USD 138,425.0 Mn by 2033, growing at a compound annual growth rate (CAGR) of 44.7% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 8,641.9 Mn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	44.70%	2033 Value Projection:	USD 138,425.0 Mn

The market for global cell and gene therapy for oncology is among the fastest-growing markets in the field of oncology therapeutics due to the growing number of cancers and the increasing need for personalized and targeted therapeutic solutions. The major firms engaged in this field are striving to develop state-of-the-art treatments such as CAR-T, TCR, and genetically engineered immunotherapy that provide better results than existing therapies.

The technological progress in gene editing, development of viral vectors, and cell engineering technologies is revolutionizing the cancer therapy process. There are several other factors contributing to the market's growth such as increased participation in clinical trials, approvals, and financial investments by biopharmaceutical companies. Moreover, rising use of precision medicine, improvements in production, and strategic partnerships are driving innovation in the cell and gene-based cancer treatment market.

Market Dynamics

The global cell and gene therapy for oncology market is spurred by an increasing burden of cancer across the globe and an increasing demand for oncology treatments that offer greater precision. Increased public awareness about new cancer therapies, coupled with advances made in techniques like CAR-T cell therapy, gene-editing, and viral vectors, is further boosting the growth of the market. Moreover, an increased number of clinical trials and investment in innovative oncology treatments by major players in biopharmaceuticals can be seen.

Some of the factors restricting the growth of the market include the high costs associated with oncology cell and gene therapy, the high costs of production, and stringent regulatory frameworks for the same. Safety issues related to the adverse side effects of such procedures, such as cytokine release syndrome, also present themselves. Nevertheless, there are ample opportunities for growth within the market, owing to the rise of allogenic and off-the-shelf therapies, wider applications for solid tumors, and increased investments in manufacturing facilities.

Key Features of the Study

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global cell and gene therapy for oncology market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study Gilead Sciences, Novartis AG, Bristol Myers Squibb, Johnson & Johnson, Legend Biotech, bluebird bio, CRISPR Therapeutics, Allogene Therapeutics, Iovance Biotherapeutics, and Adaptimmune Therapeutics
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global cell and gene therapy for oncology market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global cell and gene therapy for oncology market

Market Segmentation

Therapy Type Insights (Revenue, USD Mn, 2021 - 2033)
- Cell Therapy
- Stem Cell Therapy
- T-Cell Therapy
- Mesenchymal Stem Cell (MSC) Therapy
- Others
- Gene Therapy
- Gene Induced Immunotherapy
- Oncolytic Virotherapy
- Therapy Gene Transfer
Technology Insights (Revenue, USD Mn, 2021 - 2033)
- Cell Therapy Technology
- Autologous
- Allogeneic
- Xenogeneic
- Gene Therapy Technology
- Viral Vector-Based Gene Therapy
- Non-Viral Vector-Based Gene Therapy
Indication Insights (Revenue, USD Mn, 2021 - 2033)
- Breast Cancer
- Lung Cancer
- Prostate Cancer
- Leukaemia and Lymphoma
- Others
End User Insights (Revenue, USD Mn, 2021 - 2033)
- Hospitals and Cancer Treatment Centers
- Research and Academic Institutes
- Biotechnology and Pharmaceutical Companies
- Others
Regional Insights (Revenue, USD Mn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
Key Players Insights
- Gilead Sciences
- Novartis AG
- Bristol Myers Squibb
- Johnson & Johnson
- Legend Biotech
- bluebird bio
- CRISPR Therapeutics
- Allogene Therapeutics
- Iovance Biotherapeutics
- Adaptimmune Therapeutics

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Global Cell and Gene Therapy for Oncology Market, By Therapy Type
- Global Cell and Gene Therapy for Oncology Market, By Technology
- Global Cell and Gene Therapy for Oncology Market, By Indication
- Global Cell and Gene Therapy for Oncology Market, By End User
- Global Cell and Gene Therapy for Oncology Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
Impact Analysis
Key Highlights
Regulatory Scenario
Product Launches/Approvals
PEST Analysis
PORTER's Analysis
Market Opportunities
Regulatory Scenario
Key Developments
Industry Trends

4. Global Cell and Gene Therapy for Oncology Market, By Therapy Type, 2021-2033, (USD Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Cell Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
Stem Cell Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
T-Cell Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
Mesenchymal Stem Cell (MSC) Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
Gene Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
Gene Induced Immunotherapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
Oncolytic Virotherapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
Therapy Gene Transfer
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)

5. Global Cell and Gene Therapy for Oncology Market, By Technology, 2021-2033, (USD Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Cell Therapy Technology
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
Autologous
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
Allogeneic
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
Xenogeneic
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
Gene Therapy Technology
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
Viral Vector-Based Gene Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
Non-Viral Vector-Based Gene Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)

6. Global Cell and Gene Therapy for Oncology Market, By Indication, 2021-2033, (USD Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Breast Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
Lung Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
Prostate Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
Leukaemia and Lymphoma
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)

7. Global Cell and Gene Therapy for Oncology Market, By End User, 2021-2033, (USD Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Hospitals and Cancer Treatment Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
Research and Academic Institutes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
Biotechnology and Pharmaceutical Companies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)

8. Global Cell and Gene Therapy for Oncology Market, By Region, 2021 - 2033, Value (USD Mn)

Introduction
- Market Share (%) Analysis, 2026, 2029 & 2033, Value (USD Mn)
- Market Y-o-Y Growth Analysis (%), 2022 - 2033, Value (USD Mn)
- Regional Trends
North America
- Introduction
- Market Size and Forecast, By Therapy Type, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Technology, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, By Therapy Type, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Technology, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
  - Brazil
  - Argentina
  - Mexico
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, By Therapy Type, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Technology, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
  - Germany
  - U.K.
  - Spain
  - France
  - Italy
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, By Therapy Type, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Technology, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, By Therapy Type, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Technology, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
  - GCC Countries
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, By Therapy Type, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Technology, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country/Region, 2021 - 2033, Value (USD Mn)
  - South Africa
  - North Africa
  - Central Africa

9. Competitive Landscape

Gilead Sciences
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Novartis AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Bristol Myers Squibb
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Johnson & Johnson
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Legend Biotech
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
bluebird bio
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
CRISPR Therapeutics
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Allogene Therapeutics
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Iovance Biotherapeutics
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Adaptimmune Therapeutics
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies